$GNCA GENOCEA BIOSCIENCES, INC. Insider Trading
Get free email notifications about insider trading in GENOCEA BIOSCIENCES, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in GENOCEA BIOSCIENCES, INC.. Insider overview, share value development, latest insider transactions and email notifications about new events in GENOCEA BIOSCIENCES, INC. for free.
IRS Number: 510596811
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Trading Symbol: GNCA
Company Address: 100 ACORN PARK DRIVE CAMBRIDGE 02140
Phone number: 617-876-8191
Former name: GENOCEA BIOSCIENCES INC, date of change: 2009-03-04
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Market Capitalization: $129.13M
Prev close: $4.51
Average Daily Volume: 198,748
Days Low: $4.45
Year Low: $2.65
Year High: $8.07
GENOCEA BIOSCIENCES, INC. Latest Insider Transactions
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Duvall Diantha | CHIEF FINANCIAL OFF ... | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Duvall Diantha | CHIEF FINANCIAL OFF ... | Option Exercise | A | 3.01 | 112,500 | 338,625 | 112,500 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Duvall Diantha | CHIEF FINANCIAL OFF ... | Grant | A | 0.00 | 37,500 | 0 | 37,500 | 0 to 37.5 K |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Clark William D | President and CEO | Option Exercise | A | 0.00 | 600,000 | 0 | 600,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Clark William D | President and CEO | Option Exercise | A | 3.01 | 450,000 | 1,354,500 | 450,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Clark William D | President and CEO | Grant | A | 0.00 | 150,000 | 0 | 150,000 | 0 to 150 K |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Flechtner Jessica Baker | Chief Scientific Of ... | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Flechtner Jessica Baker | Chief Scientific Of ... | Option Exercise | A | 3.01 | 131,250 | 395,063 | 131,250 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Flechtner Jessica Baker | Chief Scientific Of ... | Grant | A | 0.00 | 43,750 | 0 | 43,750 | 0 to 43.8 K |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Option Exercise | A | 3.01 | 93,750 | 282,188 | 93,750 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Option Exercise | A | 3.01 | 93,750 | 282,188 | 93,750 | |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Grant | A | 0.00 | 31,250 | 0 | 31,250 | 0 to 31.3 K |
| Mar 17 2021 | GNCA | GENOCEA BIOSCIENCE ... | Aakalu Girish N | CHIEF BUSINESS OFFI ... | Grant | A | 0.00 | 31,250 | 0 | 31,250 | 0 to 31.3 K |